↗ public sourceswww.adisseo.com/na/products/alterion· 4 studies, 3 independent/mixed
Evidence · strong
The active substance is backed by 4 studies including meta-analyses; the verdict per claim below reflects what the literature actually shows, not the brochure. Strength reflects the active substance, not the brand.
What the manufacturer claims
Free
Captured from the product page, typed and attributed — the producer’s own statements, checked against the literature below.
Physiological
Stabilises gut flora and shifts the microbiome toward beneficial (butyrate-producing) bacteria
Physiological
Strengthens the gut barrier and controls inflammation, improving intestinal health
Performance
Improves poultry performance
Manufacturer’s own words — not independently verified. The ledger below gives the evidence verdict for each.
Claim ↔ evidence ledger
Verdict free · receipts in Power
Each claim against the studies on the active substance, with the funding split. Open a row for the studies behind the verdict.
Claim
Verdict
Evidence & funding
PhysiologicalStabilises gut flora and shifts the microbiome toward beneficial (butyrate-producing…
Supported
1 study · 0% indep
›
Read Microbiome shift toward butyrate producers is shown, mainly in studies with Adisseo involvement.
2019
Bacillus subtilis 29784 induces a butyrate-producing shift in the broiler microbiome and improves histomorphology and performanceShifted ileal microbiome (↑Bacillus, ↓Lactobacillaceae/Enterobacteriaceae), enriched butyrate producers, improved histomorphology and performance
Bacillus subtilis DSM29784 alleviates growth losses by improving intestinal health under necrotic enteritis challengeImproved intestinal health and microbiota (↑Ruminococcaceae, Bifidobacterium), reduced inflammation/apoptosis under subclinical NE
Read Performance is EFSA-recognised (applicant data).
2017
Alterion NE® (Bacillus subtilis DSM 29784) for chickens for fattening and reared for laying — EFSA FEEDAP opinionViable spores at ≈1 × 10^8 CFU/kg; authorised as a gut flora stabiliser to improve chicken performance (QPS strain)
Why these studies The evidence for a proprietary product is the evidence for its active substance. These are the studies (meta-analyses first) behind the verdicts above, with funding labelled.
Year
Study & effect size
Funding
Type
Access
2017
Alterion NE® (Bacillus subtilis DSM 29784) for chickens for fattening and reared for laying — EFSA FEEDAP opinionViable spores at ≈1 × 10^8 CFU/kg; authorised as a gut flora stabiliser to improve chicken performance (QPS strain)
Bacillus subtilis 29784 induces a butyrate-producing shift in the broiler microbiome and improves histomorphology and performanceShifted ileal microbiome (↑Bacillus, ↓Lactobacillaceae/Enterobacteriaceae), enriched butyrate producers, improved histomorphology and performance
Bacillus subtilis DSM29784 alleviates growth losses by improving intestinal health under necrotic enteritis challengeImproved intestinal health and microbiota (↑Ruminococcaceae, Bifidobacterium), reduced inflammation/apoptosis under subclinical NE
728×90 — direct-sold creative, or a responsive Google AdSense unit when unsold
Analysis & tools
◆ Power
The working map a maker won’t give you — built only from the evidence on this page. Nothing here is marketing.
◆ Power view
Open the analyst workbench
Dose benchmark, the independent-vs-sponsored split, the pooled meta-analysis effects, the contradictions and the gaps — all derived from the studies above.
Dose: label vs effective trial range vs EU max
Independence-of-evidence breakdown
Pooled meta-analysis effect sizes
Compare · CSV / JSON · API
Dose benchmark
Label / recommended≈1 × 10^8 CFU/kg
Effective in trials≈1 × 10^8 CFU/kg
EU maximumPer authorisation conditions
A spore probiotic, stable to pelleting; benefit is clearest under enteric challenge.
EFSA assessed this product’s protected form. Opinion ↗
Discussion — grounded in the evidence
Alterion is a single-strain Bacillus subtilis DSM 29784 spore probiotic, EU-authorised as a poultry gut-flora stabiliser.
It shifts the microbiome toward butyrate-producing bacteria, produces anti-inflammatory metabolites and strengthens the gut barrier.
An independent necrotic-enteritis trial shows it protects gut health and growth, supporting antibiotic-reduction use.
Much of the mechanistic data is Adisseo-linked; like most probiotics, effects are clearest under enteric challenge.
Recommended dose is ≈1 × 10^8 CFU/kg, and the spore form is robust to feed processing.
Where studies disagree: Much of the mechanistic/performance evidence involves Adisseo co-authors; the strongest independent signal is the necrotic-enteritis challenge benefit. As with most probiotics, responses are larger under challenge than in clean conditions.
Gaps: Few fully independent performance meta-analyses. No product-specific patent captured.
Manufacturer’s stated mechanism (their words): A spore-forming probiotic that germinates in the gut and produces metabolites (e.g. nicotinic acid, hypoxanthine) and shifts the microbiome toward butyrate-producing bacteria, strengthening the intestinal barrier (tight-junction proteins), modulating inflammation and improving performance.
Compare & export
Put this beside alternatives on the same active substance (e.g. HMBi / other rumen-protected methionine), and take the data with you.
Sponsored
970×90 — direct-sold creative, or a responsive Google AdSense unit when unsold